CytoVeris has appointed Dr. Michael Fenn, Ph.D., Harvard University, as the newest member of its Scientific Advisory Board (SAB).
Dr. Fenn serves as the Director of Healthcare and Life Sciences at the Harvard Innovation Labs. He is a biomedical engineer, entrepreneur and startup advisor working within the Harvard innovation and entrepreneur ecosystem.
“Our SAB brings a broad range of expertise and knowledge that is critical to CytoVeris’ product design and clinical translation plans, and we are thrilled to have Michael, an accomplished scientific professional augment our interdisciplinary team in advancing our devices and realizing our mission,” said Dr. Alan Kersey, President and CEO of CytoVeris.